While glucose tolerance is widely known to deteriorate with age, there are individuals whose borderline elevated glucose does not presage development of diabetes, but there are people who do develop overt diabetes. In addition, elevated glucose may also presage other morbidities, particularly for those who show progressive deterioration in glucose control over time. This concept of the glucose trajectory has taken on recent significance with sophisticated mathematical modeling that can identify several different arcs, primarily based on longitudinal changes in fasting plasma glucose. Other trajectories, calculated on changes in glycated hemoglobin, or integrated responses to oral glucose tolerance tests, are less well characterized. The author has reviewed the literature in an attempt to clarify these different themes of age-related deterioration in glucose control, highlight conflicting definitions of glucose trajectory, and potentially identify avenues of further investigation. Genetic contributions to the risk of development of type 2 diabetes, artificial intelligence and mathematical models of diabetes risk, and the discrepancy between fasting glucose and postprandial measures, including glycated hemoglobin, in risk prediction are also considered.
Get full access to this article
View all access options for this article.
References
1.
DeFronzoRA. Glucose intolerance and aging. Diabetes Care, 1981; 4:493–501.
2.
Diabetes Canada Clinical Practice Guidelines ExpertCommittee, PunthakeeZ, GoldenbergR, et al.Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. Can J Diabetes, 2018; 42Suppl 1:S10–S15.
3.
American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care, 2015; 38Suppl:S8–S16.
4.
FajansSS. I. Identification of chemical diabetes. The definition of chemical diabetes. Metabolism, 1973; 22:211–217.
5.
BrannickB, Dagogo-JackS. Prediabetes and cardiovascular disease: Pathophysiology and interventions for prevention and risk reduction. Endocrinol Metab Clin North Am, 2018; 47:33–50.
6.
FajansSS. Treatment of chemical diabetes mellitus with sulfonylurea compounds. Metabolism, 1973; 22:373–376.
7.
TabákAG, HerderC, RathmannW, et al.Prediabetes: A high-risk state for diabetes development. Lancet, 2012; 379:2279–2290.
8.
RobertsS, BarryE, CraigD, et al.Preventing type 2 diabetes: Systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open, 2017; 7:e017184.
9.
PasseyME, ShresthaRN, BertramMY, et al.The impact of diabetes prevention on labour force participation and income of older Australians: An economic study. BMC Public Health, 2012; 12:16.
10.
PierseT, O'NeillS, DinneenSF, et al.A simulation study of the economic and health impact of a diabetes prevention programme in Ireland. Diabet Med, 2021; 38:e14540.
11.
OhnJH, KwakSH, ChoYM, et al.10-year trajectory of β-cell function and insulin sensitivity in the development of type 2 diabetes: A community-based prospective cohort study. Lancet Diabetes Endocrinol, 2016; 4:27–34.
12.
Merriam-Webster.com. Definition of trajectory. https://www.merriam-webster.com/dictionary/trajectory (Last accessed April22, 2021).
13.
SpanP. How Meaningful Is Prediabetes for Older Adults?. New York, NY: New York Times, 2021.
14.
RooneyMR, RawlingsAM, PankowJS, et al.Risk of progression to diabetes among older adults with prediabetes. JAMA Intern Med, 2021; 181:511–519.
15.
WagnerR, HeniM, TabákAG, et al.Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med, 2021; 27:49–57.
16.
TangO, MatsushitaK, CoreshJ, et al.Mortality implications of prediabetes and diabetes in older adults. Diabetes Care, 2020; 43:382–388.
17.
ZhengF, YanL, YangZ, et al.HbA1c, diabetes and cognitive decline: The English Longitudinal Study of Ageing. Diabetologia, 2018; 61:839–848.
18.
AnsteyKJ, Sargent-CoxK, EramudugollaR, et al.Association of cognitive function with glucose tolerance and trajectories of glucose tolerance over 12 years in the AusDiab study. Alzheimers Res Ther, 2015; 7:48.
19.
YashinAI, ArbeevKG, AkushevichI, et al.Exceptional survivors have lower age trajectories of blood glucose: Lessons from longitudinal data. Biogerontology, 2010; 11:257–265.
20.
LeRoithD, BiesselsGJ, BraithwaiteSS, et al.Treatment of diabetes in older adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2019; 104:1520–1574.
21.
HaJ, ShermanA. Type 2 diabetes: One disease, many pathways. Am J Physiol Endocrinol Metab, 2020; 319:E410–E426.
22.
BergmanRN, IderYZ, BowdenCR, et al.Quantitative estimation of insulin sensitivity. Am J Physiol, 1979; 236:E667–E677.
23.
Abdul-GhaniMA, TripathyD, DeFronzoRA. Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care, 2006; 29:1130–1139.
24.
ZavaroniI, ReavenG. Insulin-resistance and associated risk factors for coronary heart disease as seen in families. Diabete Metab, 1991; 17(1 Pt 2):109–111. PMID: 1936465.
25.
LawsA, StefanickML, ReavenGM. Insulin resistance and hypertriglyceridemia in nondiabetic relatives of patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1989; 69:343–347.
26.
FacchiniF, ChenYD, ClinkingbeardC, et al.Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension. Am J Hypertens, 1992; 5:694–699.
27.
ElbeinSC, HasstedtSJ, WegnerK, et al.Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab, 1999; 84:1398–1403.
28.
DupuisJ, LangenbergC, ProkopenkoI, et al.New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet, 2010; 42:105–116.
29.
FlorezJC, JablonskiKA, McAteerJB, et al.; Diabetes Prevention Program Research Group. Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program. PLoS One, 2012; 7:e44424.
30.
WheelerE, LeongA, LiuCT, et al.Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. PLoS Med, 2017; 14:e1002383.
31.
MoonJY, LouieTL, JainD, et al.A genome-wide association study identifies blood disorder-related variants influencing hemoglobin A1c with implications for glycemic status in U.S. Hispanics/Latinos. Diabetes Care, 2019; 42:1784–1791.
32.
SarnowskiC, LeongA, RaffieldLM, et al.; TOPMed Diabetes Working Group; TOPMed Hematology Working Group; TOPMed Hemostasis Working Group; National Heart, Lung, and Blood Institute TOPMed Consortium. Impact of rare and common genetic variants on diabetes diagnosis by hemoglobin A1c in multi-ancestry cohorts: The Trans-Omics for Precision Medicine Program. Am J Hum Genet, 2019; 105:706–718.
33.
LeongA, LimVJY, WangC, et al.Association of G6PD variants with hemoglobin A1c and impact on diabetes diagnosis in East Asian individuals. BMJ Open Diabetes Res Care, 2020; 8:e001091.
34.
MaruthurNM, GribbleMO, BennettWL, et al.The pharmacogenetics of type 2 diabetes: A systematic review. Diabetes Care, 2014; 37:876–886.
35.
YuW, LiuT, ValdezR, et al.Application of support vector machine modeling for prediction of common diseases: The case of diabetes and pre-diabetes. BMC Med Inform Decis Mak, 2010; 10:16.
36.
DinhA, MiertschinS, YoungA, et al.A data-driven approach to predicting diabetes and cardiovascular disease with machine learning. BMC Med Inform Decis Mak, 2019; 19:211.
37.
NilashiM, Bin IbrahimO, MardaniA, et al.A soft computing approach for diabetes disease classification. Health Informatics J, 2018; 24:379–393.
38.
ManiruzzamanM, KumarN, Menhazul AbedinM, et al.Comparative approaches for classification of diabetes mellitus data: Machine learning paradigm. Comput Methods Programs Biomed, 2017; 152:23–34.
39.
MishraS, TripathyHK, MallickPK, et al.EAGA-MLP-an enhanced and adaptive hybrid classification model for diabetes diagnosis. Sensors (Basel), 2020; 20:4036.
40.
IslamMM, RahmanMJ, Chandra RoyD, et al.Automated detection and classification of diabetes disease based on Bangladesh demographic and health survey data, 2011 using machine learning approach. Diabetes Metab Syndr, 2020; 14:217–219.
41.
ChoubeyDK, KumarM, ShuklaV, et al.Comparative analysis of classification methods with PCA and LDA for diabetes. Curr Diabetes Rev, 2020; 16:833–850.
42.
Shankaracharya, OdedraD, SamantaS, et al.Computational intelligence-based diagnosis tool for the detection of prediabetes and type 2 diabetes in India. Rev Diabet Stud, 2012Spring; 9:55–62.
43.
WangC, LiL, WangL, et al.Evaluating the risk of type 2 diabetes mellitus using artificial neural network: An effective classification approach. Diabetes Res Clin Pract, 2013; 100:111–118.
44.
SilvaK, LeeWK, ForbesA, et al.Use and performance of machine learning models for type 2 diabetes prediction in community settings: A systematic review and meta-analysis. Int J Med Inform, 2020; 143:104268.
45.
WangY, LiuS, ChenR, et al.A novel classification indicator of type 1 and type 2 diabetes in China. Sci Rep, 2017; 7:17420.
46.
TolksC, AmentC, EberleC. Model-driven classification of different diabetes types within a personalized diabetes management. Annu Int Conf IEEE Eng Med Biol Soc, 2018; 2018:5818–5821.
47.
BuysschaertM, MedinaJL, BuysschaertB, et al.Definitions (and current controversies) of diabetes and prediabetes. Curr Diabetes Rev, 2016; 12:8–13.
48.
HulmanA, SimmonsRK, VistisenD, et al.Heterogeneity in glucose response curves during an oral glucose tolerance test and associated cardiometabolic risk. Endocrine, 2017; 55:427–434.
49.
van de SchootR. Latent trajectory studies: The basics, how to interpret the results, and what to report. Eur J Psychotraumatol, 2015; 6:27514.
50.
JonesBL, NaginDS, RoederK. A SAS procedure based on mixture models for estimating developmental trajectories. Soc Methods Res, 2001; 29:374–393.
51.
JonesBL, NaginDS. Advances in group-based trajectory modeling and an SAS procedure for estimating them. Soc Methods Res, 2007; 35:542–571.
52.
JinC, ChenS, VaidyaA, et al.Longitudinal change in fasting blood glucose and myocardial infarction risk in a population without diabetes. Diabetes Care, 2017; 40:1565–1572.
53.
LeeCL, SheuWH, LeeIT, et al.Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes. Diabetes Metab, 2018; 44:121–128.
54.
HulmanA, WitteDR, VistisenD, et al.Pathophysiological characteristics underlying different glucose response curves: A latent class trajectory analysis from the prospective EGIR-RISC study. Diabetes Care, 2018; 41:1740–1748.
55.
Abdul-GhaniMA, LyssenkoV, TuomiT, et al.The shape of plasma glucose concentration curve during OGTT predicts future risk of type 2 diabetes. Diabetes Metab Res Rev, 2010; 26:280–286.
56.
MasonCC, HansonRL, KnowlerWC. Progression to type 2 diabetes characterized by moderate then rapid glucose increases. Diabetes, 2007; 56:2054–2061.
57.
FerranniniE, NannipieriM, WilliamsK, et al.Mode of onset of type 2 diabetes from normal or impaired glucose tolerance. Diabetes, 2004; 53:160–165.
58.
TabákAG, JokelaM, AkbaralyTN, et al.Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. Lancet, 2009; 373:2215–2221.
59.
DanknerR, RothJ. The personalized approach for detecting prediabetes and diabetes. Curr Diabetes Rev, 2016; 12:58–65.
60.
DanknerR, DanoffA, RothJ. Can “personalized diagnostics” promote earlier intervention for dysglycaemia? Hypothesis ready for testing. Diabetes Metab Res Rev, 2010; 26:7–9.
61.
DanknerR, BergmanM, DanoffA, et al.The metabolic deterioration that antedates diabetes: Personal trajectories of HbA(1c) and fasting glucose as early indicators and possible triggers for intervention. Diabetes Metab Res Rev, 2013; 29:1–7.
62.
BergmanM. The early diabetes intervention program—Is early actually late?. Diabetes Metab Res Rev, 2014; 30:654–658.
63.
Sims WrightR, LevySA, KatzelLI, et al.Fasting glucose and glucose tolerance as potential predictors of neurocognitive function among nondiabetic older adults. J Clin Exp Neuropsychol, 2015; 37:49–60.
64.
OtsukiM, KitamuraT, TamadaD, et al.Incompatibility between fasting and postprandial plasma glucose in patients with Cushing's syndrome. Endocr J, 2016; 63:1017–1023.
65.
RyanEA, SavuA, YeungRO, et al.Elevated fasting vs post-load glucose levels and pregnancy outcomes in gestational diabetes: A population-based study. Diabet Med, 2020; 37:114–122.
66.
RosselloX, Raposeiras-RoubinS, OlivaB, et al.Glycated hemoglobin and subclinical atherosclerosis in people without diabetes. J Am Coll Cardiol, 2021; 77:2777–2791.
67.
MengozziA, Tricò D, Nesti L, et al.; RISC Investigators. Disruption of fasting and post-load glucose homeostasis are largely independent and sustained by distinct and early major beta-cell function defects: A cross-sectional and longitudinal analysis of the Relationship between Insulin Sensitivity and Cardiovascular risk (RISC) study cohort. Metabolism, 2020; 105:154185.
68.
KeC, StukelTA, ShahBR, et al.Age at diagnosis, glycemic trajectories, and responses to oral glucose-lowering drugs in type 2 diabetes in Hong Kong: A population-based observational study. PLoS Med, 2020; 17:e1003316.
69.
OgataS, WatanabeM, KokuboY, et al.Longitudinal trajectories of fasting plasma glucose and risks of cardiovascular diseases in middle age to elderly people within the general Japanese population: The Suita Study. J Am Heart Assoc, 2019; 8:e010628.
70.
BancksMP, CarnethonMR, ChowLS, et al.Fasting glucose and insulin resistance trajectories during young adulthood and mid-life cardiac structure and function. J Diabetes Complications, 2019; 33:356–362.
71.
FengX, WangG, LyuZ, et al.The association between fasting blood glucose trajectory and cancer risk in Chinese population without diabetes. Int J Cancer, 2020; 147:958–966.
72.
HuD, PengF, LinX, et al.The risk trajectory between preoperative fasting glucose and common digestive tract cancer-specific mortality in the FIESTA cohort involving 6865 Chinese patients. J Cancer, 2019; 10:4596–4602.
